Impact Biomedical Inc【IBO】株式ニュース

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth

ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company...

Form 8-K - Current report

Form S-8 - Securities to be offered to employees in employee benefit plans

Impact BioMedical Inc. to Present at The Microcap Conference

HOUSTON, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering...

Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision

HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease

HOUSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE: IBO), is thrilled to announce a...

Form 8-K - Current report

Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates

HOUSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering...

Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue

HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (“IBO”) is pleased to announce that the US...

Impact BioMedical Inc. Introduces Leadership Team to Drive Innovation and Growth

NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering...

Form 8-K - Current report

Impact BioMedical Inc. Announces the Closing of its Initial Public Offering

NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company...

All resolutions were approved by the required majority of shareholders at Universal Ibogaine Inc.'s (IBO)annual general meeting ("AGM"), which was held on October 3, 2022 in Vancouver, British Columbia. The company is a life sciences company with a mission to provide medicalized ibogaine-centered addiction care.

👍️0

harry_brat 3年前

$IBO held on to its renowned capital market advisor

UI recently announced that it has retained Mr. Shayne Nyquvest as their capital market advisor in a consulting role. Mr. Nyquvest has substantial capital markets experience, having assisted companies in the mining, cannabis, and other growing industries with strategic fund-raising initiatives for over 4 decades.

👍️0

Blue_Digital_Media 3年前

Universal Ibogaine Inc. thanks to David for his contributions to the Company during his tenure as a Director.

Watch now IBO for latest stock information.

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター